CAJ | 학술논문

目的：探讨低分子肝素治疗重度子痫前期合并胎儿生长受限患者的临床有效性与安全性。方法：收集60例该病患者，等分为两组，对照组给予常规治疗，实验组在常规治疗同时加用低分子肝素治疗。观察患者肾功能、胎儿脐血流指标及对母婴结局的影响。结果：治疗后实验组尿酸水平、白蛋白水平、24 h尿蛋白、RI值、S/D值、胎儿平均体重与常规治疗组相比显著改善（P<0.05）。实验组分娩时妊娠天数延长1周左右（P<0.05）。结论：低分子肝素治疗该病患者安全、有效。
목적：탐토저분자간소치료중도자간전기합병태인생장수한환자적림상유효성여안전성。방법：수집60례해병환자，등분위량조，대조조급여상규치료，실험조재상규치료동시가용저분자간소치료。관찰환자신공능、태인제혈류지표급대모영결국적영향。결과：치료후실험조뇨산수평、백단백수평、24 h뇨단백、RI치、S/D치、태인평균체중여상규치료조상비현저개선（P<0.05）。실험조분면시임신천수연장1주좌우（P<0.05）。결론：저분자간소치료해병환자안전、유효。
Objective: It is aimed to investigate the feasibility of expectant treatment which used low molecular weight heparin (LMWH) in patients of severe pre-eclampsia combined with intrauterine growth restriction and analyzed the influence on maternal and fetal outcomes. Methods: Sixty patients with severe pre-eclampsia with intrauterine growth restriction were divided into two groups randomly; the control group (30 cases) received the normal therapy; while the observation group (30 cases) received an additional therapy of LMWH. The influence on the renal function, the umbilical arterial blood flow parameters, and the maternal and fetal outcomes between the two groups were compared. Results: Compared with the control group, the levels of uric acid, albumin and 24 hour urine protein in the observation group were significantly improved (P<0.05). Umbilical artery blood flow parameters as indicators for determining the fetal status, the S/D and RI in the observation group were significantly lower than those in the control group (P<0.05). The birth weight of neonate between the two groups showed significant difference (P<0.05). The length of expectant treatment in the control group was significantly shorter than in the observation group (P<0.05). Conclusion: The application of LMWP in severe pre-eclampsia with intrauterine growth restriction is effective and safe.